Hospital Edouard Herriot

Hospital Edouard Herriot’s nephrology unit is conducting a broad portfolio of trials aimed at slowing the progression of chronic kidney disease and improving outcomes after transplantation. Researchers are testing new anti‑fibrotic drugs, evaluating personalized dosing algorithms for rituximab, and exploring combination therapies that address both renal injury and cardiovascular risk.

• Novel anti‑fibrotic agents for diabetic kidney disease
• Personalized rituximab protocol for membranous nephropathy
• Combination of finerenone and empagliflozin in advanced CKD
• Low‑dose rivaroxaban to reduce cardiovascular events in dialysis patients
• Setanaxib safety in Alport syndrome

The focus on chronic kidney disease reflects the department’s commitment to delivering innovative, patient‑centered solutions for conditions such as IgA nephropathy and lupus nephritis.

Clinical studies at the Lyon site target the intersection of heart disease and kidney impairment, testing therapies that lower blood pressure, lipid levels, and thrombotic risk. Trials evaluate whether precise heart‑rate control or novel lipid‑lowering antibodies can reduce mortality in high‑risk populations.

• Landolol infusion for heart‑rate reduction in septic shock
• Evolocumab to prevent cardiovascular events in CKD patients
• Low‑dose rivaroxaban for stroke prevention in advanced kidney disease
• Blood‑pressure optimization protocols in dialysis cohorts
• Antiplatelet strategy assessment in atherosclerotic disease

By integrating cardiovascular outcomes with renal endpoints, the program seeks therapies that simultaneously protect the heart and kidneys.

The department collaborates on multicenter trials focused on gastro‑enteric and pancreatic neuroendocrine cancers, evaluating peptide‑targeted radiotherapy and next‑generation somatostatin analogues. Objectives include extending progression‑free survival and improving quality of life.

• PRRT with 177Lu‑edotreotide versus standard care
• CAM2029 versus octreotide long‑acting release
• Combination chemotherapy with nab‑paclitaxel for CLDN18.2‑positive tumors
• Targeted therapy for high‑grade G2/G3 NETs
• Biomarker‑driven selection of somatostatin receptor‑positive patients

These studies highlight the use of peptide receptor radionuclide therapy as a precision approach for well‑differentiated neuroendocrine tumors.

Trials at the hospital address non‑muscle‑invasive and high‑risk bladder cancer, testing intravesical agents, FGFR‑targeted drugs, and immunotherapy combos. The goal is to reduce recurrence and avoid radical surgery.

• TAR‑200 with cetrelimab versus BCG in high‑risk NMIBC
• FGFR inhibitor for FGFR‑positive bladder cancer
• Intravesical chemotherapy optimization
• Combination of immunotherapy and targeted therapy for BCG‑refractory disease
• Assessment of disease‑free survival after personalized rituximab protocol

Emphasis on bladder‑preserving strategies aims to improve long‑term outcomes for patients with non‑muscle‑invasive urothelial carcinoma.

A series of studies explore new biologics and small molecules for lupus, psoriasis, vitiligo, and hidradenitis suppurativa, measuring skin‑clearance scores and patient‑reported outcomes. Researchers compare novel agents to standard topical or systemic therapies.

• Anifrolumab versus placebo for cutaneous lupus
• Bimekizumab versus corticosteroids for plaque psoriasis
• BIIB059 for subacute and chronic cutaneous lupus
• Targeted therapy for moderate‑to‑severe hidradenitis suppurativa
• Novel topical capsaicin for painful digital osteoarthritis

The investigations aim to deliver faster, lasting remission for conditions such as systemic lupus erythematosus and vitiligo.

Focused research on hereditary kidney conditions evaluates disease‑modifying agents and gene‑focused diagnostics. Trials assess safety and efficacy of treatments for Alport syndrome and APOL1‑associated kidney disease.

• Setanaxib safety and tolerability in Alport syndrome
• Gene‑editing feasibility for APOL1 kidney disease
• Biomarker‑guided enrollment for hereditary nephropathies
• Combination therapy to reduce proteinuria in genetic nephropathy
• Long‑term outcomes of early intervention in pediatric renal disease

By targeting the underlying genetic mechanisms, the program hopes to alter disease trajectory for patients with hereditary kidney disorders.

The site’s intensive care and surgery teams evaluate interventions to improve survival and wound healing in severe burns, septic shock, and acute respiratory failure. Studies compare high‑dose vitamin C, antibiotic stewardship protocols, and prophylactic strategies for graft integration.

• High‑dose intravenous vitamin C in severe burn injury
• Personalized diagnostic algorithm to reduce antibiotics in COPD exacerbations
• Antibiotic prophylaxis versus placebo for excision‑autograft surgery
• Steroid ± isavuconazole regimen for immunocompromised ARF
• Photodynamic therapy (TOOKAD) for low‑grade upper tract urothelial cancer

These efforts aim to lower mortality and accelerate recovery for patients facing critical illness or extensive thermal injury.